 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
17 News |  |
- ||| BI 54903 / Boehringer Ingelheim
New P1 trial: Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat (clinicaltrials.gov) - Aug 21, 2014
P1, N=56, Completed, Sponsor: Boehringer Ingelheim
- | BI 54903 / Boehringer Ingelheim, Striverdi Respimat (olodaterol) / Boehringer Ingelheim
New P1 trial: Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat (clinicaltrials.gov) - Aug 21, 2014
P1, N=32, Completed, Sponsor: Boehringer Ingelheim
- | BI 54903 / Boehringer Ingelheim, Striverdi Respimat (olodaterol) / Boehringer Ingelheim
New P1 trial: Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat (clinicaltrials.gov) - Aug 21, 2014
P1, N=36, Completed, Sponsor: Boehringer Ingelheim
- BI 54903 / Boehringer Ingelheim
Enrollment change: Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat (clinicaltrials.gov) - Jul 25, 2012
P2, N=29, Terminated, Sponsor: Boehringer Ingelheim Pharmaceuticals
N=23 --> 29
- BI 54903 / Boehringer Ingelheim
Trial withdrawal: Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids (clinicaltrials.gov) - Nov 21, 2011
P2, N=0, Withdrawn, Sponsor: Boehringer Ingelheim Pharmaceuticals
N=23 --> 29 Not yet recruiting --> Withdrawn
- BI 54903 / Boehringer Ingelheim
Trial withdrawal: Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone (clinicaltrials.gov) - Nov 21, 2011
P2, N=0, Withdrawn, Sponsor: Boehringer Ingelheim Pharmaceuticals
Not yet recruiting --> Withdrawn Not yet recruiting --> Withdrawn
- BI 54903 / Boehringer Ingelheim
Enrollment change: Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids (clinicaltrials.gov) - Nov 21, 2011
P2, N=0, Withdrawn, Sponsor: Boehringer Ingelheim Pharmaceuticals
Not yet recruiting --> Withdrawn N=453 --> 0
- BI 54903 / Boehringer Ingelheim
Enrollment change: Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone (clinicaltrials.gov) - Nov 21, 2011
P2, N=0, Withdrawn, Sponsor: Boehringer Ingelheim Pharmaceuticals
N=453 --> 0 N=453 --> 0
- BI 54903 / Boehringer Ingelheim, Striverdi Respimat (olodaterol) / Boehringer Ingelheim
Trial withdrawal: Olodaterol Bridging Study in Asthma (clinicaltrials.gov) - Nov 20, 2011
P2, N=0, Withdrawn, Sponsor: Boehringer Ingelheim Pharmaceuticals
N=453 --> 0 Recruiting --> Withdrawn
- BI 54903 / Boehringer Ingelheim, Striverdi Respimat (olodaterol) / Boehringer Ingelheim
Enrollment change: Olodaterol Bridging Study in Asthma (clinicaltrials.gov) - Nov 20, 2011
P2, N=0, Withdrawn, Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting --> Withdrawn N=189 --> 0
- BI 54903 / Boehringer Ingelheim
Trial termination: Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS) (clinicaltrials.gov) - Nov 15, 2011
P2, N=30, Terminated, Sponsor: Boehringer Ingelheim Pharmaceuticals
N=189 --> 0 Recruiting --> Terminated
- BI 54903 / Boehringer Ingelheim
Trial termination: Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat (clinicaltrials.gov) - Nov 15, 2011
P2, N=29, Terminated, Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting --> Terminated Recruiting --> Terminated
- BI 54903 / Boehringer Ingelheim
Trial termination: Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS). (clinicaltrials.gov) - Nov 15, 2011
P2, N=9, Terminated, Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting --> Terminated Recruiting --> Terminated
- BI 54903 / Boehringer Ingelheim
New P2 trial: Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids (clinicaltrials.gov) - Oct 23, 2011
P2, N=0, Withdrawn, Sponsor: Boehringer Ingelheim Pharmaceuticals
- BI 54903 / Boehringer Ingelheim
New P2 trial: Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone (clinicaltrials.gov) - Oct 23, 2011
P2, N=0, Withdrawn, Sponsor: Boehringer Ingelheim Pharmaceuticals
- BI 54903 / Boehringer Ingelheim, Striverdi Respimat (olodaterol) / Boehringer Ingelheim
New P2 trial: Olodaterol Bridging Study in Asthma (clinicaltrials.gov) - Aug 24, 2011
P2, N=0, Withdrawn, Sponsor: Boehringer Ingelheim Pharmaceuticals